Medicare seniors get drug coinsurance tied to real prices, not inflated list prices
S. 2617 — Reducing Drug Prices for Seniors Act. · Filed by Jacky Rosen (D-NV) · 1 cosponsor · Introduced Jul 31, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare Part D drug plans to calculate patient coinsurance (the percentage of drug cost patients pay) based on the drug's actual negotiated price after discounts, not the inflated list price, starting in 2026. Seniors would pay less out-of-pocket when the net price is lower than the list price, shifting the calculation to reflect what insurers actually pay for drugs.
Why we flagged it
The bill's sole operative mechanism is a pricing calculation change in Medicare Part D that reduces senior out-of-pocket costs by tying coinsurance to actual negotiated prices rather than list prices. This is a direct consumer-protection measure within the existing Medicare framework.
What the text implies
- Pharmaceutical manufacturers may respond by raising list prices further to offset the reduced coinsurance burden, since the bill only constrains what seniors pay—not what manufacturers charge or what plans pay.
- The bill's carve-out for drugs in paragraphs (8) and (9) (specialty tier and catastrophic coverage) means high-cost biologics and drugs in the catastrophic phase remain unaffected, limiting the bill's reach to mid-tier drugs.
The full analysis lists 4 implications of this text.
Who stands to gain
Medicare Part D beneficiaries (seniors); Medicare Advantage plans with Part D coverage (reduced coinsurance liability)